Peter van Santbrink
Research analyst
- Name
- Ing. P.J. van Santbrink
- Telephone
- 071 5276076
- santbrin@lacdr.leidenuniv.nl
Peter van Santbrink is technician at the Division of Biopharmaceutics.
Research analyst
- Faculty of Science
- LACDR
- Divisie Biotherapeutics
- Delfos L., Depuydt M.A.C., Chemaly M., Coyle S., Schaftenaar F.H., Santbrink P.J. van, Lindenbergh P.P., Bernabé Kleijn M.N.A., Costello C., Power C.A., Coll R., Peace A., Gregory-Ksander M., Foks A.C., Kuiper J., McGilligan V., Bot I. & (2025), NLRP3 inflammasome inhibition by the novel bispecific antibody InflamAb attenuates atherosclerosis in apolipoprotein e–deficient mice, JACC: Basic to Translational Science 10(6): 826-840.
- Mol J. de, Smit V., Barnabé Kleijn M.N.A., Santbrink P.J. van, Bot I. & Foks A.C. (2025), Immunosenescence accelerates atherosclerosis development in AAV-PCSK9 mouse model, GeroScience 47: 6549-6563.
- Schaftenaar F.H., Dam A.D. van, Bruin G. de, Depuydt M.A.C., Mol J., Amersfoort J., Douna H., Meijer M., Kröner M.J., Santbrink P.J. van, Bernabé Kleijn M.N.A., Puijvelde G.H.M. van, Florea B.I., Slütter B., Foks A.C., Bot I., Rensen P.C.N. & Kuiper J. (2024), Immunoproteasomal inhibition with ONX-0914 attenuates atherosclerosis and reduces white adipose tissue mass and metabolic syndrome in mice, Arteriosclerosis, Thrombosis, and Vascular Biology 44(6): 1346–1364.
- Bot I., Delfos L., Hemme E., Bernabé Kleijn M.N.A., Santbrink P.J. van, Foks A.C., Kovanen P.T., Jouppila A. & Lassila R. (2024), Treatment with APAC, a dual antiplatelet anticoagulant heparin proteoglycan mimetic, limits early collar-induced carotid atherosclerotic plaque development in Apoe-/- mice, Atherosclerosis 397: 118567.
- Hemme E., Depuydt M.A.C., Santbrink P.J. van, Wezel A., Smeets H.J., Foks A.C., Kuiper J. & Bot I. (2024), Leukemia inhibitory factor receptor inhibition by EC359 reduces atherosclerotic stenosis grade in Ldlr-/- mice, European Journal of Pharmacology 985: 177121.
- Depuydt M.A.C., Vlaswinkel F.D., Hemme E., Delfos L., Bernabe Kleijn M.N.A., Santbrink P.J. van, Foks A.C., Slütter B., Kuiper J. & Bot I. (2022), Blockade of the BLT1-LTB4 axis does not affect mast cell migration towards advanced atherosclerotic lesions in LDLr-/- mice, Scientific Reports 12(1): 18362.
- Amersfoort J., Schaftenaar F.H., Douna H., Santbrink P.J. van, Puijvelde G.H.M. van, Slütter B., Foks A.C., Harms A., Moreno-Gordaliza E., Wang Y., Hankemeier T., Bot I., Chi H. & Kuiper J. (2021), Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells, Cardiovascular Research 117(5): 1309-1324.
- Nahon J.E., Hoekstra M., Havik S.R., Santbrink P.J. van., Dallinga-Thie G.M., Kuivenhoven J.A., Geerling J.J. & Eck M. van (2018), Proteoglycan 4 regulates macrophage function without altering atherosclerotic lesion formation in a murine bone marrow-specific deletion model, Atherosclerosis 274: 120-127.
- Amersfoort J., Schaftenaar F.H., Douna H., Santbrink P.J. van, Kröner M.J., Puijvelde G.H.M. van, Quax P.H.A., Kuiper J. & Bot I. (2018), Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner, Atherosclerosis 275: 214-224.
- Nahon J.E., Hoekstra M., Havik S.R., Santbrink P.J. van, Dallinga-Thie G.M., Kuivenhoven J.A., Geerling J.J. & Eck M. van (2018), Corrigendum to "Proteoglycan 4 regulates macrophage function without altering atherosclerotic lesion formation in a murine bone marrow-specific deletion model", Atherosclerosis 279: 132-132.
- Amersfoort J., Douna H., Schaftenaar F.H., Foks A.C., Kröner M.J., Santbrink P.J. van, Puijvelde G.H.M. van, Bot I. & Kuiper J. (2018), Defective Autophagy in T Cells Impairs the Development of Diet-Induced Hepatic Steatosis and Atherosclerosis, Frontiers in Immunology 9: 2937.
- Bot I., Ortiz Zacarias N.V., Witte W.E. de, Vries H. de, Santbrink P.J. van, Velden D. van der, Kroener M.J., Berg D.J. van den, Stamos D., Lange E.C.M. de, Kuiper J., IJzerman A.P. & Heitman L.H. (2017), A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy, Scientific Reports 2017(7): 52.
- Heijden T. van der, Kritikou E., Venema W., Duijn J. van, Santbrink P.J. van, Slütter B., Foks A.C., Bot I. & Kuiper J. (2017), NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report, Arteriosclerosis, Thrombosis, and Vascular Biology 37(8): 1457-1461.
- Foks A.C., Puijvelde G.H.M. van, Wolbert J., Kröner M.J., Frodermann V., Heijden T. van der, Santbrink P.J. van, Boon L., Bot I. & Kuiper J. (2016), CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice, Cardiovascular Research 111(3): 252-261.
- Frodermann V., Duijn J. van, Puijvelde G.H.M. van, Santbrink P.J. van, Lagraauw H.M., Vries M.R. de, Quax P.H.A., Bot I., Foks A.C., Jager S.C. de & Kuiper J. (2016), Heat-killed Staphylococcus aureus reduces atherosclerosis by inducing anti-inflammatory macrophages, Journal of Internal Medicine 279(6): 592-605.
- Kritikou E., Puijvelde G.H.M. van, Heijden T. van der, Santbrink P.J. van, Swart M., Schaftenaar F.H., Kroner M.J., Kuiper J. & Bot I. (2016), Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice, Scientific Reports 6: 37585.
- Frodermann V., Duijn J. van, Pel M. van, Santbrink P.J. van, Bot I., Kuiper J. & Jager S.C. de (2015), Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development, Scientific Reports 5: 15559.
- Frodermann V., Puijvelde G.H. van, Wierts L., Lagraauw H.M., Foks A.C., Santbrink P.J. van, Bot I., Kuiper J. & Jager S.C. de (2015), Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a novel therapy for atherosclerosis, Journal of Immunology 194(5): 2208-2218.
- Bot I., Daissormont I.T., Zernecke A., Puijvelde G.H.M. van, Kramp B., Jager S.C. de, Sluimer J.C., Manca M., Hérias V., Westra M.M., Bot M., Santbrink P.J. van, Berkel T.J.C. van, Su L., Skjelland M., Gullestad L., Kuiper J., Halvorsen B., Aukrust P., Koenen R.R., Weber C. & Biessen E.A. (2014), CXCR4 blockade induces atherosclerosis by affecting neutrophil function, Journal of Molecular and Cellular Cardiology 74: 44-52.
- Lagraauw H.M., Westra M.M., Bot M., Wezel A., Santbrink P.J. van, Pasterkamp G., Biessen E.A.L., Kuiper J. & Bot I. (2014), Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation, Atherosclerosis 235(1): 196-203.
- Foks A.C., Ran I.A., Wasserman L., Frodermann V., Borg M.N. ter, Jager S.C. de, Santbrink P.J. van, Yagita H., Akiba H., Bot I., Kuiper J. & Puijvelde G.H.M. van (2013), T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology 33(11): 2558-2565.
- Foks A.C., Ran I.A., Frodermann V., Bot I., Santbrink P.J. van, Kuiper J. & Puijvelde G.H.M. van (2013), Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development, PLoS ONE 8(12): e83134.
- Bot M., Veldhoven P.P. van, Jager S.C.A. de., Johnson J., Nijstad N., Santbrink P.J. van, Westra M.M., Hoeven G. van der, Gijbels M.J., Mueller-Tidow C., Varge G., Tietge U.J.F., Kuiper J., Berkel T.J.C. van, Nofer J.R., Bot I. & Biessen E.A.L. (2013), Hematopoietic Sphingosine 1-Phosphate Lyase Deficiency Decreases Atherosclerotic Lesion Development in LDL-Receptor Deficient Mice, PLoS ONE 8(5): e63360.
- Calpe-Berdiel L., Zhao Y., Graauw M. de, Ye D., Santbrink P.J. van, Mommaas A.M., Foks A., Bot M., Meurs I., Kuiper J., Mack J.T., Eck M. van, Tew K.D. & Berkel T.J.C. van (2012), Macrophage ABCA2 deletion modulates intracellular cholesterol deposition, affects macrophage apoptosis, and decreases early atherosclerosis in LDL receptor knockout mice, Atherosclerosis 223(2): 332-341.
- Calpe-Berdiel L., Zhao Y., Graauw M. de, Ye D., Santbrink P.J. van, Mommaas A.M., Foks A.C., Bot M., Meurs I., Kuiper J., Mack J.T., Eck M. van, Tew K.D. & Berkel T.J.C. van (2012), Macrophage ABCA2 deletion modulates intracellular cholesterol deposition, affects macrophage apoptosis, and decreases early atherosclerosis in LDL receptor knockout mice, Atherosclerosis 223(2): 332-341.
- Bot I., Vries H. de, Korporaal S.J.A., Foks A.C., Bot M., Veldhoven J.P.D., Borg M.N.D. ter, Santbrink P.J. van, Berkel T.J. van.C., Kuiper J. & Ijzerman A.P. (2012), Adenosine A(2B) Receptor Agonism Inhibits Neointimal Lesion Development After Arterial Injury in Apolipoprotein E-Deficient Mice, Arteriosclerosis, Thrombosis, and Vascular Biology 32(9): 2197-2205.
- Foks A.C., Bot I., Frodermann V., Jager S.C. de, Borg M. ter, Santbrink P.J. van, Yagita H., Kuiper J. & Puijvelde G.H.M. van (2012), Interference of the CD30-CD30L pathway reduces atherosclerosis development, Arteriosclerosis, Thrombosis, and Vascular Biology 32(12): 2862-2868.
- Foks A.C., Bot I., Frodermann V., Jager S.C.A. de, Borg M. ter, Santbrink P.J. van, Yagita H., Kuiper J. & Puijvelde G.H.M. van (2012), Interference of the CD30-CD30L pathway reduces atherosclerosis development, Immunology 137: 478-478.
- Jager S.C. de, Canté-Barrett K., Bot I., Husberg C., Puijvelde G.H.M. van, Santbrink P.J. van, Yndestad A., Oever J.M. van den, Kuiper J., Berkel T.J.C. van, Lipp M., Zwaginga J.J., Fibbe W.E., Aukrust P. & Biessen E.A. (2009), Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras, Transplantation 88(5): 631-639.
- Rensen P.C., Sliedregt L.A.J.M., Santbrink P.J. van, Ferns M., Schifferstein H.N.J., Leeuwen S.H., Souverein J.H., Berkel T.J.C. van & Biessen E.A. (2006), Stimulation of liver-directed cholesterol flux in mice by novel N-acetylgalactosamine-terminated glycolipids with high affinity for the asialoglycoprotein receptor, Arteriosclerosis, Thrombosis, and Vascular Biology : .
- Rensen P.C.N., Sliedregt L.A.J.M., Santbrink P.J. van, Ferns M., Schifferstein H.N.J., Leeuwen S.H., Souverijn J.H.M., Berkel T.J.C. van & Biessen E.A.L. (2006), Stimulation of liver-directed cholesterol flux in mice by novel N-acetylgalactosamine-terminated glycolipids with high affinity for the asialoglycoprotein receptor, Arteriosclerosis, Thrombosis, and Vascular Biology 26: 169-175.
- Rensen P.C.N., Sliedregt L.A.J.M., Santbrink P.J. van, Ferns M., Schifferstein H.N.J., Leeuwen SH van, Souverijn J.H.M., Berkel T.J.C. van & Biessen E.A.L. (2006), Stimulation of liver-directed cholesterol flux in mice by novel N-acetylgalactosamine-terminated glycolipids with high affinity for the asialoglycoprotein receptor, Arteriosclerosis, Thrombosis, and Vascular Biology 26: 169-175.
- Bot I., Guo J., Eck M. van, Santbrink P.J. van, Groot P.H., Hildebrand RB, Seppen J., Berkel T.J.C. van & Biessen E.A.L. (2005), Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo, Blood 106: 1147-1153.
- Sliedregt L.A.J.M., Rensen P.C.N., Rump E.T., Santbrink P.J. van, Bijsterbosch M.K., Valentijn A.R.P.M., Marel G.A. van der, Boom J.H. van, Berkel T.J.C. van & Biessen E.A.L. (1999), Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor, Journal of Medicinal Chemistry 42: 609-618.
- Rensen P.C.N., Sliedregt L.A.J.M., Santbrink P.J. van, Berkel T.J.C. van & Biessen E.A.L. (1998), Novel glycolipids with high affinity for the hepatic asialoglycoprotein receptor are potent cholesterol-lowering agents, Circulation 98: I-451.